Targeting PTEN May Prevent Skin Cancer
7/27/2011
Scientists believe they have identified a role for PTEN, a known tumor suppressor, in removing DNA damage derived from UVB radiation, a known risk factor for non-melanoma skin cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. Yu-Ying He, Ph.D...
'Hidden' Cancer Cells Not A Factor In Early-Stage Breast Cancer Survival Rates
7/27/2011
A new study shows that removing lymph nodes due to the presence of occult, or microscopic, cancer cells found in the sentinel lymph node the one closest to the tumor -- has no impact on survival outcomes of women with early-stage breast cancer. The principal investigator of the study is Armando E...
Vitamin D Relieves Joint, Muscle Pain For Breast Cancer Patients
7/27/2011
High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis. The drugs, known as aromatase inhibitors, are commonly prescribed to shrink breast tumors fueled by the hormone estrogen and help prevent cancer recurrence...
New National Program To Further Develop The Science Of Glycobiology
7/27/2011
Scientists at the University of California, San Diego School of Medicine have received a major 7-year, $18 million grant to begin translating emerging discoveries in the field of glycosciences into new discoveries and therapies related to heart, lung and blood diseases. Glycobiology is the study of glycans (carbohydrate chains) and their crucial roles in molecular and cellular biology...
Using iPS Cells To Investigate Treatment For Sickle Cell Disease
7/27/2011
Researchers from the Boston University School of Medicine (BUSM) were recently awarded a five-year $9 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to mass-produce sickle cell anemia-specific induced Pluripotent Stem (iPS) cells. Under the direction of principal investigators Martin H...
Scientists Develop New Therapy For HER2-Positive Breast Cancer
7/26/2011
Patients with HER2-positive breast cancer may soon have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Jacek Capala, Ph.D., D.Sc...
TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment...
TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment...
Opening Of Pilot Clinical Trial In Synovial Sarcoma
7/26/2011
Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri...
Discovery Of Elusive Gene That Makes Platelets Grey
7/26/2011
Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test...